Antibody–drug Conjugates (ADCs) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)

Antibody–drug Conjugates (ADCs) – Report Overview

Pacific Business Consulting’s “Antibody–drug Conjugates (ADCs) Market in 8MM – Market Outlook, Market Assessment and Market Forecast (2023-2030)” report offers a comprehensive exploration of Antibody–drug Conjugates (ADCs), encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Eight Major Markets (8MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and China.

According to the analysis by Pacific Business Consulting, the Antibody–drug Conjugates (ADCs) market is anticipated to witness a Compound Annual Growth Rate (CAGR) exceeding 15% during the forecast period from 2023 to 2030, with the market estimated to be valued at US$8.4 billion in 2022.

Antibody–drug Conjugates (ADCs), a category of targeted cancer therapies, amalgamate the specificity of monoclonal antibodies with the cytotoxic effects of potent anti-cancer drugs. While monoclonal antibodies have revolutionized cancer treatment, their efficacy may be insufficient, and traditional systemic therapies like chemotherapy can be overly toxic. ADCs, often referred to as “biological missiles,” address this gap by combining an antibody, cytotoxic payload, and a chemical linker. Approved ADCs specifically target proteins overexpressed in cancer cells, such as HER2, trop2, nectin4, EGFR, CD33, CD30, among others.

The advantages of ADCs in cancer treatment include a targeted approach, delivering cytotoxic drugs directly to cancer cells, potentially reducing systemic toxicity. ADCs can enhance the therapeutic index of potent drugs and overcome drug resistance mechanisms in certain cancers.

Ongoing research and development activities aim to expand ADC applications, involving the identification of new target antigens and optimization of components like antibody selection, linker design, and payload selection. Advances in antibody engineering techniques, including antibody fragment engineering and bispecific antibody technology, are explored to enhance ADC design and functionality.

Combination therapies involving ADCs are gaining interest, with potential synergies observed when combining ADCs with immune checkpoint inhibitors, chemotherapy, or targeted therapies. This integrated approach aims to improve treatment response and enhance patient outcomes.

Key companies covered in this study include AstraZeneca PLC, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, F. Hoffmann-La Roche, Astellas Pharma Inc., BioNTech SE, Eisai Co., Ltd., Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, Takeda Pharmaceutical Company Ltd., and LaNova Medicines Ltd.

Scope of Report

The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Antibody–drug Conjugates (ADCs) market. It also delves into the analysis of present and prospective market competition within the global Antibody–drug Conjugates (ADCs) market.

Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.

Reasons to Buy

• Develop your business strategies by gaining insights into the trends that shape and drive the Antibody–drug Conjugates (ADCs) market across the 8MM (Eight Major Markets).
• Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 8MM Antibody–drug Conjugates (ADCs) market.
• Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
• Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.

Please note that detailed pipeline analysis can be provided along with the standard scope to assist you in developing and designing your in-licensing and out-licensing strategies. This includes a review of pipeline products and technologies, along with identifying companies with the most robust pipeline.

1. Executive Summary: Antibody–drug Conjugates (ADCs)
   • Global Market Outlook: Antibody–drug Conjugates (ADCs)
2. Competitive Intelligence Analysis; Antibody–drug Conjugates (ADCs)
3. Therapeutic Sector SWOT
4. Technology Roadmap Analysis
5. Market Background
   • Drivers
   • Restraints
   • Opportunity
   • Key Market Trends
   • Key Unmet Needs
6. Antibody–drug Conjugates (ADCs): Key Marketed Products Profile – Major Approved Products
   • Product Profile
   • Regulatory Milestones
   • Safety and Efficacy
   • Clinical Development
7. Antibody–drug Conjugates (ADCs): Promising Pipeline Candidates – Major Products in Late Stage of Development
   • Product Description
   • Safety and Efficacy
   • Research and Development
8. Regulatory Landscape
9. Antibody–drug Conjugates (ADCs): Eight Major Market (8MM) – Market Analysis
   • Historical Market Analysis (US$ million), 2020-2022
   • Current and Future Market Projections (US$ million), 2023-2030
10. S. Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
11. K. Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
12. Germany Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
13. France Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
14. Italy Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
15. Spain Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
16. Japan Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
17. China Antibody–drug Conjugates (ADCs) – Market Analysis
    • Historical Market Analysis (US$ million), 2020-2022
    • Current and Future Market Projections (US$ million), 2023-2030
18. Competitive Landscape
    • Company Overview
    • Product Portfolio
    • Key Financials
    • Sales Footprint

Note – All Major Company Profiles (Count up to 20) will be covered in the report

19. Assumptions and Acronyms Used
20. Research Methodology
    • Secondary Research
    • Primary Research
    • Data Triangulation
21. Geographic Scope
    • The U.S., The U.K., Germany, France, Italy, Spain, Japan, and China
22. Copyrights and Disclaimer